Beij A., Verdonk R
Firstly, the 1-g and 4-g PV1 sVLP doses tested in the study contain 187 and 748 DU, respectively, which are much higher than a single human dose (40 DU) of commercial IPV, making it difficult to directly compare the immunogenicity of sVLP and IPV
Two other expression strategies have previously been employed to produce PV1-SC6b D-antigenic sVLP in yeast, including co-expression of P1 and an uncleavable 3CD 32 and co-expression of VP3-P2A-VP0 and VP1 or VP3-P2A-VP1 and VP0 33
Vi glutathion ng truyn, cn cn nhc v c th gy cc tai bin nguy him nh d ng thuc nng, ri lon chc nng thn, ri lon chc nng gan,
Explore our Face Tonic, with Palmitoyl Tripeptide-1 and Palmitoyl Tetrapeptide-7, for help with the appearance of fine lines and skin firmness
This is where phase III comes into play